![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Clovis Oncology’s Rubraca for Prostate Cancer
FDA Approves Clovis Oncology’s Rubraca for Prostate Cancer
May 19, 2020
The FDA has granted accelerated approval to Clovis Oncology’s Rubraca for patients with BRCA mutation-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
The approval was based on positive results from a phase 2 study. The company must verify the clinical benefit in confirmatory trials.
Rubraca is currently approved for ovarian, fallopian tube and peritoneal cancers that have been treated with two or more chemotherapies.
Upcoming Events
-
21Oct